Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Trastuzumab Deruxtecan Alone, in Combination with Anastrozole, or Followed by Chemotherapy for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Trial Status: active

This phase II trial investigates how well trastuzumab deruxtecan works alone, in combination with anastrozole, or followed by chemotherapy in treating patients with HER2 low, hormone receptor positive breast cancer. HER2 is protein involved in normal cell growth. It may be made in larger than normal amounts by some types of cancer cells which may cause cancer cells to grow more quickly. Hormone receptor positive describes cells that have a group of proteins that bind to a specific hormone such as estrogen or progesterone. These cancer cells need these hormones to grow. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. Chemotherapy drugs, such as docetaxel and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trastuzumab deruxtecan alone, in combination with anastrozole, or followed by chemotherapy may be effective in treating HER2 positive hormone receptor positive breast cancer.